Entresto vs Brilinta
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Entresto | US Brilinta | |
|---|---|---|
| Generic name | sacubitril/valsartan | ticagrelor |
| Drug class | ARNI (Neprilysin Inhibitor + ARB) | P2Y12 Platelet Inhibitor (Antiplatelet) |
| Treats | Chronic heart failure | Acute coronary syndrome, heart attack prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | AstraZeneca |
| Year approved | 2015 | 2011 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $150M | $120M |
| Common side effects | Low blood pressure, High potassium, Kidney problems, Dizziness | Bleeding, Shortness of breath, Bruising, Headache |
Frequently asked questions
Is Entresto or Brilinta better?
Neither is universally "better." Entresto (sacubitril/valsartan) and Brilinta (ticagrelor) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Entresto and Brilinta?
Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis, while Brilinta is a P2Y12 Platelet Inhibitor (Antiplatelet) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Entresto has the larger estimated TV advertising budget of the two.